NIPC Law

Human Respiratory Syncytial Virus Author NIAID   Licence CC BY 2.0   Source    Wikimedia Commons   Jane Lambert Patents Court (Mr Justice Mellor)  Pfizer Ltd v GlaxoSmithKline Biologicals SA and another 2024] EWHC 2523 (Pat) (07 Oct 202 4) Pfizer Ltd v GlaxoSmithKline Biologicals SA and anothe r [2025] EWHC 52 (Pat) (16 Jan 2025) This was a claim by Pfizer Ltd. ("Pfizer")  for the revocation of  EP (UK) 3 109 258 ("258") and EP (UK) 2 222 710 ("710")  under s.72 (1) (a)  of the Patents Act 1977 on the grounds that the inventions for which those patents were granted were not patentable.  The patents were held by  GlaxoSmithKline Biologicals SA  and  ID Biomedical Corporation of Quebec  (collectively "GSK").   The reason for the litigation was that both Pfizer and GSK had developed vaccines for respiratory syncytial virus ("RSV")  that were about to receive marketing approval in the UK....

Electron Microscope Image of Human Blood Photographers: Bruce Wetzel and Harry Schaefer Jane Lambert Patents Court  (Mr Justice Meade)  Merck Sharp & Dohme Ltd v Wyeth LLC [2020] EWHC 2636 (Pat) (15 Oct 2020) This was an action by Merck Sharp & Dohme Ltd ("MSD") for the revocation of European Patent (UK) 2,676,679  for formulations which stabilize and inhibit precipitation of immunogenic compositions which had been granted to Wyeth LLC ("Wyeth") on grounds of want of novelty, obviousness and insufficiency.  Wyeth counterclaimed for infringement and also applied for the amendment of certain claims. The trial took place between 30 June and 10 July 2020 before Richard Meade QC as he then was.  In a press release dated 4 Sept 2020, the Judicial Appointments Commission announced   that Mr Meade had been elevated to the High Court bench with effect from 7 Sept 2020. His lordship handed down his judgment in this action on 15 Oct 2020 (see  Merck ...